A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants
A phase 1/2 trial of Tislelizumab in renal cell carcinoma and melanoma, run by BeiGene, active and no longer recruiting.
Overview
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT05661955 by BeiGene, with 113 participants enrolled, started 2023-01-09 and due to reach its primary completion in 2025-05-27. Interventions recorded: BGB-A445, Tislelizumab. Conditions listed: Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma, Non-mucosal Melanoma. No results are recorded here; the registry entry is the source.
Setting
Phase 1b/2 Study Investigating the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of the Anti-OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Urothelial Carcinoma, Renal Cell Carcinoma, or Melanoma
Phase
Phase 1/2
Sponsor
BeiGene
Registry
Enrolled
113
Similar pages
not linked directly; found by shared links- TrialA Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus
- TrialTislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
- TrialRATIONALE-302
- TrialA Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
- PersonJie Wang
- TrialA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Sol
- TrialStudy of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
- PersonSamra Turajlić
Shares Renal cell carcinoma, Melanoma.